aVLFA0822p Pharmacology II - lecture

Faculty of Medicine
spring 2020
Extent and Intensity
2/0/0. 4 credit(s). Type of Completion: zk (examination).
Teacher(s)
Mgr. Petra Amchová, Ph.D. (lecturer)
doc. RNDr. Ladislava Bartošová, Ph.D. (lecturer)
doc. MUDr. Regina Demlová, Ph.D. (lecturer)
doc. PharmDr. Jan Juřica, Ph.D. (lecturer)
Mgr. MVDr. Leoš Landa, Ph.D. (lecturer)
Mgr. Jana Merhautová, Ph.D. (lecturer)
MUDr. Jana Nováková, Ph.D. (lecturer)
PharmDr. Adriána Papiež, Ph.D. (lecturer)
MUDr. Jana Pistovčáková, Ph.D. (lecturer)
PharmDr. Jitka Rychlíčková, Ph.D. (lecturer)
Mgr. Barbora Říhová, Ph.D. (lecturer)
PharmDr. Lenka Součková, Ph.D. (lecturer)
PharmDr. Ondřej Zendulka, Ph.D. (lecturer)
Renata Bláblová (assistant)
Květoslava Sedlářová (assistant)
Mgr. Martin Brož (alternate examiner)
Mgr. Kateřina Nebeská (alternate examiner)
Mgr. Kristýna Nosková (alternate examiner)
Guaranteed by
doc. MUDr. Regina Demlová, Ph.D.
Department of Pharmacology - Theoretical Departments - Faculty of Medicine
Contact Person: PharmDr. Ondřej Zendulka, Ph.D.
Supplier department: Department of Pharmacology - Theoretical Departments - Faculty of Medicine
Prerequisites (in Czech)
aVLFA0721p Pharmacology I - lecture && aVLPF0622p Pathological Phys. II - lect.
Course Enrolment Limitations
The course is also offered to the students of the fields other than those the course is directly associated with.
Fields of study the course is directly associated with
Course objectives
The aim of the course is to acquiant the students with drugs from selected pharmacotherapeutic groups.
Learning outcomes
At the end of the course student should be able choose and prescribe suitable drug for the patient with known indicication. The selection will be made with respect to all factors influencing drug safety and efficacy.
Syllabus
  • VLFA08222p - Pharmacology II lecture

    General medicine

    Spring semester 2019

  • 19. 2. 2019
  • 1. INTRODUCTION TO PSYCHOPHARMACOLOGY, ANTIPSYCHOTICS, ANTIPARKINSONICS
  • Lecture content: History and classification of psychotropic substances. Antipsychotics, antiparkinsonics – basic pharmacological review.
  • 26. 2. 2019
  • 2. ANXIOLYTICS, HYPNOSEDATIVES, ANTICONVULSANTS
  • Lecture content: Anxiolytics, hypnosedatives, anticonvulsants - basic pharmacological review. The possibilities of modulation of GABAergic neurotransmission.
  • 5. 3. 2019
  • 3. ANTIDEPRESSANTS
  • Lecture content: Pharmacological review of antidepressants and their clinical use.
  • 12. 3. 2019
  • 4. DRUGS OF DISEASES WITH CHRONIC PULMONARY OBSTRUCTION, H 1-ANTIHISTAMINES.
  • Lecture content: Effects of histamine and how to antagonize it. Classification of H 1 antihistamines. Pharmacological review of drugs used in the therapy of diseases with chronic pulmonary obstruction.
  • 19. 3. 2019
  • 5. ANTIANGIAL DRUGS
  • Lecture content: Pharmacological review of drugs used in the treatment of both acute and chronic ischemic heart disease.
  • 26. 3. 2019
  • 6. ANTIHYPERTENSIVES
  • Lecture content: Pharmacological review of antihypertensives with special focus on drugs interfering with RAAS and diuretics. Second-line antihypertensives.
  • 2. 4. 2019
  • 7. DRUGS OF HEART FAILURE, ANTIARRHYTHMICS
  • Lecture content: Review of drugs used in the therapy of acute and chronic heart failure, Pharmacological review of antiarrhytmics.
  • 9. 4. 2019
  • 8. DRUGS INFLUENCING HEMOSTASIS
  • Lecture content: Pharmacological review of anticoagulants, antiplatelets, fibrinolytics, and hemostatics.
  • 16. 4. 2019
  • 9. ANTI-INFECTIVES I - ANTIBIOTICS
  • Lecture content: Introduction/principles of ATB therapy, modes of resistance, pharmacological review of single groups of ATBs.
  • 23. 4. 2019
  • 10. ANTI-INFECTIVES II – ANTIMYCOTICS AND ANTIVIRALS
  • Lecture content: Systemic and local antimycotics; antiherpetics; pharmacotherapy of influenza; antiretrovirals; therapy of RSV and viral hepatitis – pharmacological review.
  • 30. 4. 2019
  • 11. PHARMACOLOGY OF GIT – ULCER DISEASE, ANTIEMETICS, ANTIDIARRHEALS AND LAXATIVES
  • Lecture content: Pharmacological review of drugs acting on GIT.
  • 7. 5. 2019
  • 12. CYTOSTATICS AND TARGETED THERAPY IN ONCOLOGY
  • Lecture content: Introduction. Classification of cytostatics according to their mechanisms of action. Mechanisms of resistance to anticancer drugs. Role of single nucleotide polymorphisms (SNPs) and TDM in oncology. Basic pharmacological properties of selected cytostatics. Principles of targeted therapy in oncology. Monoclonal antibodies. Protein kinase inhibitors. Targeted immunotherapy.
  • 14. 5. 2019
  • 13. THERAPY OF INTOXICATIONS
  • Lecture content: Review of most common intoxications and their symptomatology.. General principles of poisoning management. Specific antidotes in poisoning therapy.
  • 21. 5. 2019
  • 14. DRUG-DRUG INTERACTIONS
  • Lecture content: Classification of drug-drug interaction, evaluation of clinical relevance and seriousness oc drug interactions, management of drug interactions, possibilities of drug interactions monitoring, case-reports.
  • 28. 5. 2019
  • 15. PHYTOPHARMACOLOGY AND PHARMACOGNOSY
  • Lecture content: Natural sources of medicines, selected groups of herbal active components, herbal preparations. The most common herbal poisons.
Literature
    required literature
  • RANG, H. P. Rang & Dale's pharmacology. 8th ed. [Edinburgh]: Churchill Livingstone, 2016. xv, 760. ISBN 9780702053627. info
    recommended literature
  • WHALEN, Karen. Pharmacology. Edited by Richard Finkel - Thomas A. Panavelil. 6th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2015. xi, 664. ISBN 9781451191776. info
    not specified
  • Study materials in the IS, course aVLFA0822p and aVLFA0822c
  • Exam question outlines in the IS
Teaching methods
lectures
Assessment methods
The final evaluation of the course contains also results of the tests from practicals of both semesters and results of colloquium test.

The final mark is calculated by following method:

Relative weight of the mark from tests: 40 %
Relative weight of the mark from oral exam: 60 %

To calculate mark from the tests the following method will be used:
The summary score from all tests in courses VLFA07212c, VLFA07212p, VLFA08222c, and VLFA08222p is 230 pts. Minimum to pass through the course to the oral exam is 116 pts.
A = 191-230 pts
B = 171-190 pts
C = 153-170 pts
D = 135-152 pts
E = 117-134 pts
F = less than 116 pts

To calculate mark from the oral examthe following method will be used:
Three different questions are chosen by students from three different sets of questions at oral exam. Moreover the student answers additional questions of examinator. Each of drawn questions has relative weight of 20 % and the additional questions relative weight of 40% in the final mark of the oral exam. When student is evaluated by F for any of these questions the overall rating of oral exam is also F.

In case of success with the ROPOT test, but classification F from the oral part, students enter the oral part next time and for the final mark the score from the last ROPOT attempt is u
Language of instruction
English
Further comments (probably available only in Czech)
The course is taught annually.
Information on the extent and intensity of the course: 30.
Listed among pre-requisites of other courses

Zobrazit další předměty

Teacher's information

General pharmacology:

1. Basic legislation related to drug use, Sources of information on drugs and medicinal products

2. Types of pharmacotherapy, rules of rational and safe phramacotherapy. The question of drug misuse.

3. Preclinical and clinical trials, stages

4. Pharmacology, sub-branches, origin of drugs, drug names

5. Solid and gaseous pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics

6. Semi-solid and liquid pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics

7. Routes of drug administration – overview, charakteristics

8. Inhibition and induction of enzymes in pharmacokinetics and pharmacodynamics of drugs - examples

9. Drug absorption, presystemic elimination, drug bioavailability

10. Drug distribution, volume of distribution, redistribution. General principles of drug movement through the body.

11. Pharmacokinetic processes of the first and zero order, saturation pharmacokinetics, drug accummulation

12. Drug elimination, t0,5, KE, Cl

13. Drug biotransformation – stages, examples

14. Drug excretion (ways of excretion, possibilities of their influence)

15. Therapeutic monitoring of drugs (TDM)

16. Pharmacokinetics of single, repeated and continual drug administration

17. Nonspecific modes of drug action – examples of drugs

18. Receptor theory of drugs mode of action

19. Synergism and antagonism in drug effect (pharmacokinetics, pharmacodynamics)

20. Dose – response curves, types of doses, drug anamnesis, patient‘s adherence

21. Specific modes of drug action – target structures, examples of drugs

22. Adverse drug reactions (types, categories, examples)

23. Pharmacovigilance, drug safety

24. Primary resistance of the patient to the treatment. Influence of repeated administration on drug efficacy - examples of tolerance and tachyphylaxis

25. Factors influencing the drug effect – examples

26. Pharmacotherapy in elderly, the influence of co-morbidities on drug effect, polypharmacy

27. Pharmacotherapy in pediatric population, in breastfeeding women. Drugs influencing breast feeding.

28. Pharmacotherapy in pregnancy, drug teratogenicity

29. Drug interactions - overview, examples

30. Principles of biological treatment – classification, technology, examp=les of clinical use

31. Pharmacogenetics, influence of genetic polymorfisms on pharmacokinetics and pharmacodynamics of drugs

Special pharmacology:

1. Sympathomimetics - overview of single classes and their indications, examples of drugs

2. Sympatholytics - overview of single classes and their indications, examples of drugs

3. Cholinomimetics

4. Cholinolytics

5. Antispasmodics - GIT + UGT.

6. Glucocorticoids

7. Immunostimulants + immunosuppressants (except glucocorticoids)

8. Antidiabetics (except insulines)

9. Insulins

10. Sex hormones - contraception and HRT

11. Drugs targeting H-P axis and their indications (except contraception and HRT)

12. Uterotonics and tocolytics

13. Opioid analgesics

14. NSAIDs, non-opioid analgesics, antimigraine agents

15. Antiuratics, antirheumatics incl. DMARDs

16. General anesthetics

17. Local anesthetics

18. Muscle relaxants

19. Antipsychotics

20. Drugs of neurogenerative diseases (Parkinson’s disease; dementia)

21. Anticonvulsants

22. Nootropics, cognitives

23. Hypnosedatives, anxiolytics

24. Antidepressants - iMAO+SSRI+NDRI

25. Antidepressants - tricyclic, NASSA, SDRI, SNRI, SSRE, SMS

26. Psychotomimetics, drugs used in ADHD

27. Antiasthmatics, drugs used in COPD

28. Antitussives, mucoactive drugs

29. H1 antihistamines

30. Hypolipidemics, anti-obesity drugs

31. Antihypertensives – drugs targeting RAAS

32. Antihypertensives – diuretics and aldosterone antagonists

33. Antihypertensives beta blockers + central antihypertensives

34. Antihypertensives - calcium channel blockers, α1 lytics

35. Antiangial agents

36. Antiarrhythmics

37. Drugs used in heart failure

38. Antiplatelet agents

39. Fibrinolytics, antifibrinolytics

40. Anticoagulants

41. Antianemics, hemostatics

42. Aminoglycosides

43. Principles of antibacterial therapy – overview, modes of action, resistance, MIC, MBC

44. Lincosamides, glycopeptides, polymyxins

45. Tetracyclines + related ATBs, amphenicoles

46. Cephalosporines, monobactams

47. Penicillins, carbapenems

48. Sulphonamides, nitrofurans and nitroimidazoles

49. Macrolides and related ATBs

50. Quinolones, antituberculotics

51. Antimycotics

52. Dermatologics – overview of classes, drugs and effects

53. Antivirotics

54. Antiemetic drugs, prokinetics, antivertigo drugs

55. Laxatives, antidiarrhoics, drugs of infectious diarrhoeas

56. Antiulcer agents, hepatoprotectives and drugs influencing the production and excretion of bile

57. Alkylating cytostatics and other drugs aiming on DNA in oncology

58. Biological treatment of autoimmune diseases

59. Targeted treatment in oncology

60. Antimetabolites + hormonal therapy in oncology

61. Drugs causing addiction

62. Drugs used in the treatment of addiction

63. General principles of drug poisoning, specific antidotes and their mechanisms of action

64. Drugs for inflammatory bowel disease

65. Drugs used in erectile dysfunction and BHP

66. Drugs used in osteoporosis, pharmacology of thyroid gland

67. Vitamins

68. Antiglaucomatics and cycloplegics

„Essential drugs“

1. adrenalin/noradrenalin

2. dobutamine

3. ephedrine/pseudoephedrine

4. phenylephrine

5. oxymetazoline

6. methyldopa

7. salbutamol

8. doxazosin

9. metoprolol

10. timolol

11. atropin

12. butylscopolamine

13. fenpiverine/pitofenon

14. pilocarpine

15. rivastigmine

16. physostigmine

17. solifenacin

18. dexametasone

19. prednisone

20. cyclosporine

21. interferons

22. methotrexate

23. metformin

24. glimepiride

25. sitagliptin

26. insulin lispro

27. insulin glargine

28. ethinylestradiol

29. cyproterone

30. tibolone

31. tamoxifen

32. hexoprenaline

33. oxytocin

34. levonorgestrel

35. paracetamol/ASA

36. ibuprofen/diclofenac

37. indometacin

38. nimesulide/meloxicam

39. buprenorphine

40. morphine/naloxone

41. sufentanil

42. tramadol

43. metamizole

44. allopurinol

45. sumatriptan

46. desflurane

47. propofol

48. ketamine

49. procaine/lidocaine

50. suxamethonium

51. prilocaine

52. haloperidol

53. olanzapine

54. aripiprazole

55. levodopa/carbidopa

56. diazepam

57. buspirone

58. piracetam/pyritinol

59. gabapentin/pregabalin

60. carbamazepine

61. valproic acid

62. zolpidem

63. midazolam

64. escitalopram

65. amitriptyline

66. mirtazapine

67. lithium

68. methylphenidate

69. acetylcysteine

70. codeine

71. butamirate

72. ipratropium-bromide

73. bisulepine/cetirizine

74. atorvastatine

75. fenofibrate

76. ezetimibe

77. isosorbid dinitrate/nitroglycerin

78. hydrochlorothiazide/indapamide

79. furosemid

80. spironolactone

81. amlodipin

82. perindopril

83. telmisartan

84. warfarin

85. enoxaparin

86. clopidogrel

87. dabigatran

88. rivaroxaban

89. alteplase

90. digoxin

91. amiodarone

92. verapamil

93. levosimendan

94. doxycycline

95. co-amoxicillin

96. phenoxymethylpenicillin

97. piperacillin

98. meropenem

99. cefuroxim

100. cotrimoxazol

101. clarithromycin

102. azithromycin

103. gentamicin

104. ciprofloxacin

105. vancomycin

106. rifampicin

107. terbinafine

108. caspofungin

109. amphotericin B

110. fluconazole

111. acyclovir

112. zidovudine

113. isotretinoin

114. salicylic acid

115. ondansetron

116. moxastine

117. pantoprazol

118. famotidin

119. lactulose

120. aprepitant

121. metoclopramid

122. loperamide

123. betahistine

124. cinnarizine

125. cyclophosphamide

126. methotrexate

127. 5-fluorouracil

128. paclitaxel

129. doxorubicin

130. cisplatin

131. trastuzumab

132. imatinib

133. interferon alfa

134. nivolumab

135. methadone

136. buprenorphine

137. nalmefene

138. naltrexone

139. finasteride

140. sildenafil

141. ibandronic acid

The course is also listed under the following terms Spring 2018, spring 2019.
  • Enrolment Statistics (spring 2020, recent)
  • Permalink: https://is.muni.cz/course/med/spring2020/aVLFA0822p